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Predicting Survival in the Advanced Cancer Patient

Robert J. Miller, MD*

O

ne ofthe unfortunate aspects ofthe Medicare hospice benefit has been the tendency to let the statutory requirements
define hospice. The hospice benefit requires that physicians certify a patient as terminal, defined as a person with a medical
prognosis of six months or less (I). Physicians have objected to
this requirement, pointing out the difficulty ofmaking such predictions accurately (2). A recent United States General Accounting Office study (3) on the Medicare hospice benefit noted the
problems with this definition and recommended changes. The
Health Care Financing Adininistration. however, has resisted
changing the requirement, stating that patients need this information to have "a sound basis for choosing palliative rather than
curative care" (1). Is it possible to comply with this requirement?

Predicting Survival
Studies show that even experts in terminal care have little
ability to predict accurately time of survival for patients with advanced cancer (4-7). Most predictions are too optimistic (4.5).
For patients with advanced di.sease. age, sex, and tumor histology become irrelevant; the best prognostic tool is the pertormance status, such as the Kamofsky score (KS) (4,8,9).
From the data of the National Hospice Study, Mor et al (8)
found there was an increa.se in survival of 15 days for each increa.se in one KS level, with more variation or predictive error
occurring at higher levels. It is clearly more difficult to predict
survival with accuracy when patients are in a higher performance status. By combining data that include KS and survival
from several studies of patients with terminal cancer (4,8-11), an
almost linear inverse relationship exists between survival and
KS below 50 to 60. but a more unpredictable relationship persists above this level (Figure). Accordingly, this is not a problem
until the KS falls below 50 or 60 (defined as a patient requiring
considerable assistance or more specialized care) when a patient
is likely to require hospice care. The Karnofsky Performance
Status Scale and other commonly used host performance scales,
including the American Joint Committee on Cancer host .scale
and the Eastem Cooperative Oncology Group scale, are shown
in Table I .
Reuben et al (10) provide some practical data that clinicians
may use to predict survival in patients with advanced cancer,
based on performance status and key clinical symptoms (Tables
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2A and 2B). In patients with advanced disease there is a common terminal syndrome; the specific tumor type or metastatic
pattem is not important (12). For patients with advanced cancer
referred for possible hospice care, use ofthese tables is appropriate. The survival of patients with incurable cancer and higher
pertormance scores is less predictable and varies widely, based
on tumor type and many other variables.

Common Cancers and Metastatic Patterns
Physicians concerned with palliative care are often expected
to make accurate survival estimates for cancer patients. General
guidelines to dislinguish between incurable and terminal patients are needed.
In estimating mortality, understanding the tremendous impact of stage and severity of disease is critical, perhaps more ,so
for cancer lhan any other condition (13). Much survival data
available for patients with advanced cancer come from studies
lhat have excluded the type of patients we see in hospice care
(i.e., those with Karnofsky performance scores below 50 to 60),
and much of this data may be misleading if applied to patients
with very low performance status or advanced disease.
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Figure—Relationship ben\'een Karnofsky score and survival in
terminal cancer patients.
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Table 1
Performance Status Scales
Activity

AJCC

Normal activity
Sympiomatic but ambulatory
Ambulatory > 50%, some
assistance needed
Ambulatory < 50%. nursing
care needed
Bedridden, may need
hospitalization

IIO
HI
H2

ECOG

Table 2A
Survival in Terminal Cancer Patients
from the National ttospice Study*
KS
90-100
70-80
50-60

113

30-40

H4

10-20

Karnofsky
Score
10-20
30-40
50-1-

Karnofsky Performance Groups
Moribund, requiring active support
Disabled, requiring special medical care
Care for their own personal needs

Survival by
Performance Status
16,8 days
49,8 days
86,1 days

*From Reuben DB, Mor V, Hiris J, Clinical symptoms and length of survival in patients
wilh lerminal cancer Arch Inlern Med 1988; 148; 1586-91,

AJCC = American Joinl Commillee on Cancer, ECOG = Eastern Cooperative Oncology
Group, KS = Karnofsky score.

Bone metastases
As bone metastases are generally not life-threatening, their
impact on survival is generally small. In patients with otherwise
indolent disease (e.g., breast or prostate cancer), survival may be
prolonged and prognosis is better judged from other criteria.
Representative survival statistics from studies by the Radiation
Therapy Oncology Group (14,15) demonstrated large variation
in survival, with prolonged survival in breast cancer (73 weeks
for single metastasis, 34 to 48 weeks for multiple metastases),
intermediate survival in prostate cancer and most other histologies (39 and 33 weeks for single metastasis, 30 and 16 weeks for
multiple metastases), and generally the shortest survival for lung
cancer (14 weeks for single metastasis, 12 to 22 weeks for multiple metastases).
Brain metastases
The survival of untreated brain metastases is usually stated as
I month with no treatment, 2 months with steroids only, and 3 to
4 months with palliative radiotherapy (16,17). Survival in patients selected for surgery is much longer.
Within the large series of patients treated with palliative radiotherapy, survival is related strongly to the underiying neurologic functional category (18,19) (working: 27 weeks; homebound: 17 weeks; hospitalized: 14 weeks; comatose: 5 weeks).
Use of favorable criteria such as controlled primary tumor, no
other distant metastases, age < 60 years, and performance score
> 70 can generate survival rates as short as 1.8 months (with
none of these factors) to 7.4 months (with all of them) (20). Patients who respond to therapy can be expected to survive much
longer (complete response: 33 to 49 weeks; partial response: 20
weeks; no response: 9 to 14 weeks) (18-21). Histology is not as
important as functional state, for once these patients develop
brain metastases the survival is similar (18,22,23).
Hepatic metastases
The survival of patients with untreated hepatic metastases is
reported to be from 2.5 to 8 months (24,25). Much recent literature, which includes patients suitable for aggressive therapy
with infusion pumps, reports survival of 13 to 25 months (26,
27), with responders living much longer than nonresponders (31
months versus 16 months) (28). Patients treated by surgical re-
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section may have prolonged survival, with as many as one-third
surviving 5 years (25).
Survival based on the primary histology shows some variation (colon: 5 to 9 months; gastric: 6 months; breast: 6 months;
pancreas: 2.4 months) (29). Data based on performance status or
liver function provide for more accurate survival estimates (29,
30) (16 months for KS > 80 versus 7.2 months for KS < 80; 18.9
months if lactate dehydrogenase is < 500 versus 8.6 months if
lactate dehydrogena.se is > 500), Degree of liver involvement
also has prognostic significance (< 20%: 24.5 months; 21% to
40%; 13.6 months; 41% to 60%: 8.8 months; > 60%.: 6.1
months).
Breast cancer
In typical series of chemotherapy for metastatic breast cancer,
survival ranges from 12 to 57 months (31-37). reflecfing the
marked variability as well as the frequently indolent nature of
this disease.
Patients whose tumors are estrogen receptor-positive will
survive longer than those whose tumors are estrogen receptornegative (30 months versus 12 to 18 months) (38). Those who
have a complete response to therapy have prolonged survival
(36 to 47 months) (39).
The extent of disease and performance status affect survival
as might be expected (KS 100: 34 weeks: KS 80-90: 24 to 27
weeks; KS 60-70: 14 to 21 weeks; KS 40-50: 7 to 9 weeks; KS
20-30: 3 to 5 weeks) (40).
Colon cancer
Some typical reports of survival of patients with colon cancer
treated with current chemotherapy show wide variation (4 to 16
months) (41-47). Most ofthese patients succumb to hepatic metastases.
Lung cancer
The survival of patients with untreated inoperable lung cancer is from 8 to 36 weeks (48). With palliative doses of radiation
survival is 20 to 26 weeks (49); with various chemotherapy regimens survival is 13 to 86 weeks (50,51). A patient with an excellent response to chemotherapy may live substantially longer
than a patient with no response (e.g.. 83 weeks versus 15 weeks)
(52).
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Table 2B
Survival with Terminal Cancer Based on
Karnofsky Score and Key Symptoms*
Number of
Symptoms
0
1
2
3
4
5

KS 10-20
53 days
38-46 days
29-38 days
23-.30 days
19-23 days
16 days

Survival Period
KS 30-40
1 15 days
83-98 days
69-82 days
50-65 days
41-49 days
36 days

Curative
KS 50+
172 days
125-191 days
95-123 days
75-97 days
62-74 days
54 days

^'From Reuben DB, Mor V, Hiris J, Clinical symptoms and lenglh of survival in paiienis
wilh lerminal cancer. Arch Inlern Med 1988:148:1586-91,
Nole: Symploms found lo have signiticanl, indcpendenl prognostic value: dry moulh,
dyspnea, eating problems/anorexia, dysphagia, and weighl loss,
KS = Karnofsky score.

Performance status is critical in this group, and by utilizing
such data Lanzotti et al (53) and Minna et al (54) were able to develop groups with survival from < 1 week to 30 weeks.
Prostate cancer
The survival of patients with metastatic prostate cancer is
generally long, with 23% to 30% surviving 5 years (55,56). Median survival with hormonal therapy is 2 to 3 years, but once the
cancer becomes resistant to hormones the patients live only 4 to
8 months (57,58). Performance status has less prognostic significance in patients receiving hormonal treatment (59).

Recommendations
With use ofthese data, physicians can be more accurate with
survival estimates. However, there is need for better data, data
that are more representative of the patients seen in the private
setting. As community-based tumor registry data become available, we should have more accurate figures. These numbers may
be useful to the physician but need not necessarily be shared
with the patient.
One of the first rules of communicating with incurable patients is never give them a specific estimate of survival. When
patients ask how much time they have left to live, it is generally
wise to find out why they want to know. Often specific concems. such as whether they should be placed on permanent disability or whether they can plan for their summer vacation, can
be answered with some certainty. By clarifying the question we
often can provide an answer that is honest and helpful to the patient but avoids the use of numbers which become fixed in the
patient's mind, cause psychological distress, and are almost
never correct anyway.
Nevertheless, we are required under Medicare to certify a patient as terminal with 6 months to live. Fortunately, this regulation has been modified with the addition of the phrase "...ifthe
terminal illness runs its normal course" (60). This subtle but important change allows a doctor to say to a patient who has not
given up the hope of living longer that "based on the stage of
your disease you qualify for the hospice program, but knowing
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Table 3
Classification of Treatments in Patients with Cancer

Goal:
Tumor;
Morbidily;
Psychology:
Hospice;

Cure
Eradicate
Major
Win
No

PalliativeActive
Prolong survival
Artest growth
Moderate
Fight
No

PalliativeSymptomatic

Supportive

Symptoms
Kcspiinse
Minor
Live with it
Maybe

Symptoms
None
None
Surrender
Yes

you, I'm betting you'll beat those numbers." This meets the legal requirements of the statutes but allows the physician to remain "on the patient's side" psychologically, to allow the patient to maintain hope, and to avoid "condemning" the patient.
The only "appropriate" terminal care is that which is consistent with the goals ofthe patient. Use of terms such as "palliative
therapy" or "aggressive therapy" do not convey enough information to be useful. Understanding the patient's goals, mindset, and tolerance of morbidity is necessary in order to determine
the appropriateness of therapy (Table 3).
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